Portal de Periódicos da CAPES

ESTROGENIC MANAGEMENT OF BENIGN PROSTATISM, INCLUDING EARLY AND POOR‐RISK CASES: 7‐YEAR EXPERIENCE*

1966; Wiley; Volume: 14; Issue: 7 Linguagem: Inglês

10.1111/j.1532-5415.1966.tb02895.x

1532-5415

H. J. Roberts,

Pelvic floor disorders treatments

Journal of the American Geriatrics SocietyVolume 14, Issue 7 p. 657-701 Article ESTROGENIC MANAGEMENT OF BENIGN PROSTATISM, INCLUDING EARLY AND POOR-RISK CASES: 7-YEAR EXPERIENCE* H. J. Roberts M.D., Corresponding Author H. J. Roberts M.D. West Palm Beach, FloridaDirector, Palm Beach Institute for Medical Research; Consulting Staff, St. Mary's Hospital, West Palm Beach.Address: Palm Beach Institute for Medical Research, Inc., 304 Twenty-Seventh Street, West Palm Beach, Florida 33407.Search for more papers by this author H. J. Roberts M.D., Corresponding Author H. J. Roberts M.D. West Palm Beach, FloridaDirector, Palm Beach Institute for Medical Research; Consulting Staff, St. Mary's Hospital, West Palm Beach.Address: Palm Beach Institute for Medical Research, Inc., 304 Twenty-Seventh Street, West Palm Beach, Florida 33407.Search for more papers by this author First published: July 1966 https://doi.org/10.1111/j.1532-5415.1966.tb02895.xCitations: 13 †From the Mannow Research Laboratory, Palm Beach Institute for Medical Research, West Palm Beach, Florida. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Scott, W. W.: Growth and development of the human prostate, in Biology of the Prostate and Related Tissues. Monograph 12, National Cancer Institute. Washington, D.C., Government Printing Office, 1963, p. 111. 2Reduction in mortality from prostatic disease, Statistical Bull. (Metropolitan Life Ins. Co.) 45: 7 (Dec.) 1964. 3Huggins, C.: Introduction, in Biology of the Prostate and Related Tissues. Monograph 12, National Cancer Institute. Washington, D.C., Government Printing Office, 1963. 4Wildbolz, E.: Elective prostatectomy, Proc. Roy. Soc. Med. 51: 1029, 1958. 5Damrau, F.: Benign prostatic hypertrophy: amino acid therapy for symptomatic relief, J. Am. Geriatrics Soc. 10: 426, 1962. 6Roberts, H. J.: Control of bleeding after dental extraction during anticoagulant therapy; with particular reference to estrogenic prophylaxis, J.A.M.A. 175: 962, 1961. 7Roberts, H. J.: Oral and intravenous estrogens in the treatment and prevention of bleeding associated with long-term anticoagulant therapy, J. Am. Geriatrics Soc. 9: 184, 1961. 8Roberts, H. J.: The control of nonvariceal gastrointestinal hemorrhage, Med. Times 89: 603, 1961. 9Roberts, H. J.: Treatment of diabetic retinopathy with estrogens, J. Am. Geriatrics Soc. 9: 655, 1961. 10Roberts, H. J.: The control of gastro-intestinal hemorrhage in cirrhosis by combined adrenocortical and estrogenic therapy, J. Am. Geriatrics Soc. 9: 976, 1961. 11Roberts, H. J.: Estrogenic control of corticosteroid-induced bruising, with a commentary on estrogen-corticosteroid interrelationships, J. Am. Geriatrics Soc. 11: 374, 1963. 12Ende, M., and Jacobson, P.: Treatment of benign prostatic hypertrophy with estrogen administered intravenously: report of seventeen cases, J. Am. Geriatrics Soc. 5: 676, 1957. 13Kennedy, B. J.: Systemic effects of androgenic and estrogenic hormones in advanced breast cancer, J. Am. Geriatrics Soc. 13: 230, 1965. 14Kahle, J. J., and Maltry, E.: Treatment of hyperplasia of the prostate with diethylstilbestrol and diethylstilbestrol dipropionate: a preliminary report, New Orleans M. & S. J. 93: 121, 1940. 15Feder, H. H., and Whalen, R. E.: Feminine behavior in neonatally castrated and estrogen-treated male rats, Science 147: 306, 1965. 16Roberts, H. J.: Difficult Diagnosis: A Guide to the Interpretation of Obscure Illness. Philadelphia, W. B. Saunders Co., 1958. 17Roberts, H. J.: Menopausal edema, J.A.M.A. 176: 1053, 1961. 18Preedy, J. R. K., and Aitken, E. H.: The effect of estrogen on water and electrolyte metabolism. I. The normal, J. Clin. Invest. 35: 423, 1956. 19Preedy, J. R. K., and Aitken, E. H.: The effect of estrogen on water and electrolyte metabolism. II. Hepatic disease, J. Clin. Invest. 35: 430, 1956. 20Preedy, J. R. K., and Aiken, E. H.: The effect of estrogen on water and electrolyte metabolism. III. Cardiac and renal disease, J. Clin. Invest. 35: 443, 1956. 21Dignam, W. S.; Voskian, J., and Assali, N. S.: Effects of estrogens on renal hemo-dynamics and excretion of electrolytes in human subjects, J. Clin. Endocrinol. & Metab. 16: 1032, 1956. 22Cupesock, G.: Hormonal treatment of benign prostatic hypertrophy with estrogens and progesterone, Orientacion Med. 11: 503, 1962. 23Hertz, R.: Tullner, W. W.; Westfall, B. B.; Morrow, A. G., and Emge, M. K.: Intravenous administration of massive dosages of estrogen to human subject; blood levels attained, Proc. Soc. Exper. Biol. & Med. 72: 187, 1949. 24Roberts, H. J.: Aplastic anemia due to pentachlorophenol and tetrachlorophenol, South. M. J. 56: 632, 1963. 25Mueller, M. N., and Kappas, A.: Impairment of hepatic excretion of sulfobromophthalein (BSP) by natural estrogens, Tr. A. Am. Physicians 77: 248, 1964. 26Geller, J.; Bora, R.; Roberts, T.; Newman, H.; Lin, A., and Silva, R.: Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function, J.A.M.A. 193: 115, 1965. 27Roberts, H. J.: Use of a low-sodium formula as an improved Karell diet, with emphasis upon the outpatient management of heart failure and lymphedema, Am. Heart J. 65: 33, 1963. 28Roberts, H. J.: Supportive adrenocortical steroid therapy in acute and subacute cerebrovascular accidents, with particular reference to brain-stem involvement, J. Am. Geriatrics Soc. 6: 686, 1958. 29Marmorston, J.; Magdison, O.; Kuzma, O., and Moore, F. J.: Estrogen therapy in men with myocardial infarction: side-effects with increasing dosage and time, J.A.M.A. 174: 241, 1960. 30Harrison, F. G., Jr.: The why, what, and how of prostatic repair, Consultant (Smith, Kline & French Laboratories) November, 1963. 31Marshall, V. F.: Textbook of Urology. New York, Paul B. Hoeber, 1956, p. 67. 32Flocks, R. H.: Benign prostatic hypertrophy: its diagnosis and management, Med. Times 92: 519, 1964. 33Noble, R. L.: Effect of synthetic estrogenic substances on body-growth and endocrine organs of rats, Lancet 2: 192, 1938. 34Huggins, C., and Clark, P. J.: Quantitative studies of prostatic secretion. II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs, J. Exper. Med. 72: 747, 1940. 35Cook, E. N.: Diagnosis and treatment of benign prostatic hyperplasia, Postgrad. Med. 33: 446, 1963. 36Vernon, S.: Nocturia in the elderly male, J. Am. Geriatrics Soc. 6: 411, 1958. 37Kaufman, J. J., and Goodwin, W. E.: Hormonal management of the benign obstructing prostate: use of combined androgen-estrogen therapy, J. Urol. 81: 165, 1959. 38Bennett, H. S.; Baggenstoss, A. H., and Butt, H. R.: The testis, breasts and prostate of men who die of cirrhosis of the liver, Am. J. Clin. Path. 20: 814, 1950. 39Stumpf, H. H., and Wilens, S. L.: Inhibitory effects of portal cirrhosis of the liver on prostatic enlargement, A.M.A. Arch. Int. Med. 91: 304, 1953. 40Robson, M. C.: The incidence of benign prostatic hyperplasia and prostatic carcinoma in cirrhosis of the liver, J. Urol. 92: 307, 1964. 41Coppage, W. S., Jr., and Cooner, A. E.: Testosterone in human plasma, New England J. Med. 273: 902, 1965. 42Valati, G., and Prosser, I.: Behavior of serum acid mucopolysaccharide in patients with prostatic hypertrophy and in patients with prostatic carcinoma (Ital.), Cir. Pat. Sper. 10: 439, 1962. 43Greene, L. F.: Prostatic hyperplasia: common misconceptions, Postgrad. Med. 32: 44, 1962. 44Plorde, J. J.; Kennedy, R. P.; Bourne, H. H.; Ansell, J. S., and Petersdorf, R. G.: Course and prognosis of prostatectomy; with a note on the incidence of bacteremia and effectiveness of chemoprophylaxis, New England J. Med. 272: 269, 1965. 45 aHoltgrewe, H. L., and Valk, W. L.: Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2,015 cases, J. Urol. 87: 450, 1962. bHoltgrewe, H. L., and Valk, W. L.: Late results of transurethral prostatectomy, J. Urol. 92: 51, 1964. 46Bobelis, C. K.: Premarin Intravenous in prostatic surgery, Illinois Med. J. 117: 231, 1960. 47Wayne, L.; Glueck, H. I.; Brodine, C., and Coots, M.: Effect of intravenous estrogens on an inhibitor of hyaluronidase and on clotting factors in blood, Proc. Soc. Exper. Biol. & Med. 116: 85, 1964. 48Phillips, L. L.; Turksoy, R. N., and Southam, A. L.: Influence of ovarian function on the fibrinolytic enzyme system. II. Influence of exogenous steroids, Am. J. Obst. & Gynec. 82: 1216, 1961. 49 aKirschner, M. A.; Lipsett, M. B., and Collins, D. R.: Plasma ketosteroids and testosterone in man: a study of the pituitary-testicular axis, J. Clin. Invest. 44: 657, 1965. bDavis, T. E.; Lipsett, M. B., and Korenman, S. G.: Suppression of testosterone production by physiologic doses of 2α-methyldihydrotestosterone propionate, J. Clin. Endocrinol. & Metab. 25: 476, 1965. 50 aBalsano, F.; DiNoto, V., and Pappalardo, A.: Serum-insulin response to glucose, Lancet 2: 41, 1965. bGlass, S. J.: The rationale of treating benign prostatic hypertrophy with combinations of testosterone and estrogen, J. Am. Geriatrics Soc. 4: 358, 1956. 51Price, D., and Williams-Ashman, H. G.: The accessory reproductive glands of mammals, in Sex and Internal Secretion, ed. by W. C. Young. Baltimore, Williams & Wilkins Co., 1961, ed. 3, chapter 6. 52Jensen, E. V.: Comparison of androgens and estrogens as to their fate in target tissues, in Biology of the Prostate and Related Tissues. Monograph 12, National Cancer Institute. Washington, D. C., Government Printing Office, 1963, p. 317. 53Huggins, C.: Discussion of paper by Price and Williams-Ashman (51). 54Saunders, F. J.: Some aspects of relation of structure of steroids to their prostate-stimulating effects, in Biology of the Prostate and Related Tissues. Monograph 12, National Cancer Institute. Washington, D. C., Government Printing Office, 1963, p. 139. 55Wesson, M. B.: The value of testosterone to men past middle age, J. Am. Geriatrics Soc. 12: 1149, 1964. 56Roberts, H. J.: Observations on the treatment of postherpetic neuralgia with nandrolone, J. Am. Geriatrics Soc. 13: 166, 1965. 57Roberts, H. J.: The syndrome of narcolepsy and diabetogenic (“functional”) hyperinsulinism, with special reference of obesity, diabetes, idiopathic edema, cerebral dysrhythmias and multiple sclerosis (200 patients), J. Am. Geriatrics Soc. 12: 926, 1964. 58Farnsworth, W. E., and Brown, J. R.: Metabolism of testosterone by the human prostate, J.A.M.A. 183: 436, 1963. 59Barron, E. S. G., and Huggins, C.: Metabolism of isolated prostatic tissue, J. Urol. 51: 630, 1944. 60Ogawa, G., and Kambe, A.: Effects of steroid hormones on the proliferation of HeLa and HL cells (Jap.), Rinsho Fujinka-Sanka 17: 931, 1963. 61 aOmura, J.; Okita, K., and Fujita, Y.: Relationship between benign prostate hypertrophy and protein anabolic hormones (Jap.), Saishin Igaku 19: 1906, 1962. bKoga, Y.; Okamura, Y.; Imamura, Y., and Tanaka, A.: Studies of the effect of androgen on the genesis of carcinoma of the cervix (Jap.), Horumon To Rinsho 12: 585, 1964. 62 aDorfman, R. I., and Shipley, R. A.: Androgens. New York, John Wiley and Sons, Inc. 1956. bKennedy, B. J., and Gilbersten, A. S.: Increased erythropoiesis induced by androgenic hormone therapy, New England J. Med. 256: 719, 1957. cGrayhack, J. T.: Effect of testosterone-estradiol administration on citric acid and fructose content of rat prostate, Endocrinology 77: 1068, 1965. 63 Dorland's Illustrated Medical Dictionary, 23rd ed. Philadelphia, W. B. Saunders Co., 1957, p. 1115. 64Ewert, E. E.: Evolution of early and late bladder neck obstruction in the adult male, Postgrad. Med. 38: 170, 1965. 65Wollaeger, E. E., and Scribner, B. H.: Delayed excretion of water with regular nocturnal diuresis in patients with nontropical sprue (idiopathic steatorrhea), Gastroenterology 19: 224, 1951. 66Dick, V. S.: Unrecognized prostatism, J.A.M.A. 148: 925, 1952. 67Dorfman, R. I.: Antiandrogens, in Biology of the Prostate and Related Tissues. Monograph 12, National Cancer Institute. Washington, D. C., Government Printing Office, 1963, p. 161. 68Goodwin, D. A.; Rasmussen-Taxdal, D. S.; Ferreria, A. A., and Scott, W. W.: Estrogen inhibition of androgen-maintained prostatic secretion in the hypophysectomized dog, J. Urol. 86: 134, 1961. 69Brandes, D., and Bourne, G. H.: Histochemistry of some aspects of prostate pathology, in Biology of the Prostate and Related Tissues. Monograph 12, National Cancer Instititute. Washington, D. C., Government Printing Office, 1963, p. 29. 70O'Conor, V. J., Jr.; Desautels, R. E.: Pryor, J. W.; Munson, P. L., and Harrison, J. H.: Studies of hormonal changes in relation to cancer of the prostate: a progress report, J. Urol. 81: 468, 1959. 71 aCoppage, W. S., Jr., and Cooner, A. E.: Testosterone in human plasma, Clin. Res. 13: 70, 1965. bForchielli, E.; Rao, G. S.; Sarda, I. R.; Gibree, N. B.; Pochi, P. E.; Strauss, J. S., and Dorfman, R. I.: Effect of ethinyloestradiol on plasma testosterone levels and urinary testosterone excretion in man, Acta endocrinol, 50: 51, 1965. 72Silberberg, M., and Silberberg, R.: Modifying action of estrogen on the evolution of osteoarthrosis in mice of different ages, Endocrinology 72: 449, 1963. 73Casey, J. H.; Moxham, A., and Nabarro, J. D. N.: Idiopathic hirsutism: seasonal variation of hair-growth and response to estrogen administration, Lancet 1: 587, 1964. 74Laron, Z., and Kowadlo-Silbergeld, A.: Fat mobilizing effect of estrogen, Acta endocrinol. 48: 125, 1965. 75Wugmeister, I.: Le traitement do I'hypertrophie de la prostate par doses massives de folliculin, Paris méd. 1: 535, 1937. 76Epstein, B. J.; Raheja, M. C.; Frow, E., and Morse, W. I.: Estrogen (E) synthesis in normal and castrate men: quantitative studies on the precursor role of testosterone (T), Clin. Res. 13: 241, 1965. 77 aGwinup, G.; Rosewater, S., and Hamur, G. J.: Studies of the mechanism of production of breast enlargement in familial gynecomastia, Clin. Res. 13: 244, 1965. bZumoff, B.; Fishman, J.; Gallagher, T. F., and Hellman, L.: Abnormal estrogen metabolism in male breast cancer. Program, 57th Annual Meeting of the American Society for Clinical Investigation, Atlantic City, May 3, 1965. cSouthren, A. L.; Ross, H.; Sharma, D. C.; Gordon, G.; Weingold, A. B., and Dorfman, R. I.: Plasma concentration and biosynthesis of testosterone in the syndrome of feminizing testes, J. Clin. Endocrinol. & Metab. 25: 518, 1965. dFrench, F. S.; Baggett, B.; Van Wyk, J. J.; Talbert, L. M.; Hubbard, W. R.; Johnston, F. R., and Weaver, R. P.: Testicular feminization: clinical, morphological, and biochemical studies, J. Clin. Endocrinol. & Metab. 25: 661, 1965. 78Hamburger, C., and Halvorsen, K.: Om udskillsen af androgens og ostrogene substanser samt gonadotropin i urine hos normale maend i far skellige aldre, Ugskr. f. Laeger 104: 1443, 1942. 79Acevedo, H. F., and Goldzieher, J. W.: The metabolism of (14C) estrone by hypertrophic and carcinomatous human prostate tissue, Biochem. & Biophys. Acta 97: 571, 1965. 80Acevedo, H. F., and Goldzieher, J. H.: Further studies on the metabolism of 4-(14C) androstene-3, 17-dione by normal and pathological human prostate tissue, Biochem. & Biophys. Acta 97: 564, 1965. 81Farnsworth, W. E.: 10-Demethylation and aromatization of testosterone by the human prostate. Abstract 67, Program of the 47th Annual Meeting of The Endocrine Society, New York City, June 17–19, 1965. 82Teilum, G.: Oestrogen production by Sertoli cells in the etiology of benign senile hypertrophy of the human prostate, Acta endocrinol. 4: 43, 1950. 83Berthrong, M.; Goodwin, W. E., and Scott, W. W.: Estrogen production by the testis, J. Endocrinol. 9: 579, 1949. 84Lynch, K. M., Jr., and Scott, W. W.: The lipoid content of the Leydig cell and Sertoli cell in the human testis as related to age, benign prostatic hyperplasia and prostatic cancer, J. Urol. 64: 767, 1950. 85Segal, S. J.; Marberger, H., and Flocks, R. H.: Tissue distribution of stilbestrol diphosphate; concentration in prostatic tissue, J. Urol. 81: 474, 1959. 86 aLauritzen, C., and Velibese, S.: Clinical investigation of a long-acting oestriol (polyoestriol phosphate), Acta endocrinol. 38: 73, 1961. bBorglin, N. E., and Rappe, A.: Effect of estriol on breast engorgement and lactation in nonnursing mothers, Am. J. Obst. & Gynec. 81: 335, 1961. bBradshaw, L. R. H.; Bagness, J. E.; Pyrah, L. N., and Roper, F. P.: A study of steroid excretion in patients with prostatic cancer, Invest. Urol. 1: 466, 1964. 87 aMay, J. A., and Stimmel, B. F.: Do patients with cancer of prostate gland show abnormal metabolism of therapeutic doses of natural estrogens? J. Urol. 59: 396, 1948. bBauld, W. S.; Milne, I. G., and Givner, M. L.: Abnormality of estrogen metabolism in men with myocardial infarction, J. Clin. Invest. 35: 689, 1956. cBershon, I., and Oelofse, P. J.: Urinary oestrogen levels in myocardial infarction, South African M. J. 32: 979, 1958. dCameron, C. B.: Urinary excretion of oestrone, oestradiol-17β and oestriol in patients with chronic liver damage, J. Endocrinol. 15: 199, 1957. eBrown, J. B.; Crean, G. P., and Ginsburg, J.: Oestrogen metabolism and excretion in liver disease, Gut 5: 56, 1964. fFlickinger, G. L.; Murawec, T., and Touchstone, J. C.: Free and conjugated estrogens of an ovarian cystadenoma and granulosa cell tumor, J. Clin. Endocrinol. & Metab. 25: 1231, 1965. 88 aKatz, F. H., and Kappas, A.: Effects of estriol on aldosterone secretion rate and hormone binding globulins in man. Abstract 54, Program of the 47th Annual Meeting of the Endocrine Society, New York City, June 17–19, 1965. bSpellacy, W. N., and Schoeller, K. L.: Insulin and glucose changes in the blood of subjects taking oral contraceptives, Clin. Res. 13: 407, 1965. 89 aBrown, J. B.: Endocrine Aspects of Breast Cancer. Edinburgh, E. & S. Livingston Ltd., 1958, p. 197. bBrown, J. B.; Falconer, C. W. A., and Strong, J. A.: Urinary oestrogens of adrenal origin in women with breast cancer, J. Endocrinol. 19: 52, 1959. cMarmorston, J.; Crowley, L. G.; Myers, S. M.; Stern, E., and Hopkins, C. E.: II. Urinary excretion of estrone, estradiol, and estriol by patients with breast cancer and benign breast disease, Am. J. Obst. & Gynec. 92: 460, 1965. 90 aMarmorston, J.; Gierson, H. W.; Myers, S. M., and Stern, E.: Urinary excretion of estrone, estradiol, and estriol by patients with lung cancer and emphysema, Am. Rev. Resp. Dis. 92: 417, 1965. bBerndt, B.: Cited in Medical World News, November 5, 1965, p. 33. 91Shimkin, M. B.; Shimkin, P. M., and Andervont, H. B.: Effect of estrogens on kidney weight in mice, J. Nat. Cancer Inst. 30: 135, 1963. 92Schiff, M., and Burn, H. F.: Effect of intravenous estrogens on ground substance, Arch. Otolaryng. 73: 43, 1961. 93Schiff, M., and Burn, H. F.: The effect of estrogens on mast cells and enzymes in connective tissue metabolism in humans, Laryngoscope 71: 765, 1961. 94Zachariae, F.: Autoradiographic (35S) and histochemical studies of sulfomucopolysaccharides in the rabbit uterus, oviducts and vagina; variations under hormonal influence, Acta endocrinol. 29: 118, 1958. 95Wayne, L.; Coots, M.; Glueck, H. I.; Baum, G. L.; Pecora, L., and Putnam, L.: The effect of intravenous estrogen on tissues and capillaries as measured by coagulation tests, intradermal hyaluronidase serum inhibitor, and pulmonary diffusion studies, J. Lab. & Clin. Med. 58: 970, 1961. 96Katz, F. H., and Kappas, A.: The effect of natural estrogens on hydroxyproline excretion in man, (abstract) J. Clin. Invest. 44: 1063, 1965. 97Talalay, P., and Williams-Ashman, H. G.: I. Mechanisms of hormone action: participation of steroid hormones in the enzymatic transfer of hydrogen, Recent Progr. Hormone Res. 16: 1, 1960. 98Groth, D. P., and Brandes, D.: Correlative electron-microscope and biochemical studies on the effect of estradiol on the rat ventral prostate, J. Ultrastruc. Res. 4: 166, 1960. 99Goldstein, D. P.: Influence of estrogen on neutrophil alkaline phosphatase (NAP) activity. Abstract 75, Program of the 47th Meeting of The Endocrine Society, New York City, June 17–19, 1965. 100McDonald, D. F., and Latta, M. J.: Anaerobic glycolysis of human prostatic adenoma: in vitro inhibition by estrogen and by androgen and estrogen, Endocrinology 59: 159, 1956. 101Lasnitzki, I.: The effect of estrone alone and combined with 20-methylcholanthrene on mouse prostate gland grown in vitro, Cancer Res. 14: 632, 1964. 102 aSpaziani, E.: Influence of estradiol, puromycin and actinomycin-D on hexose transport in rat uterus. Abstract 72, Program of the 47th Meeting of The Endocrine Society, New York City, June 17–19, 1965. bWilson, J. D.: Studies on the mechanism of enhancement of protein synthesis by estradiol, (abstract) J. Clin. Invest. 42: 994, 1963. cUi, H., and Mueller, G. C.: The role of RNA synthesis in early estrogen action, Fed. Proc. 22: 409, 1963. 103Berczeller, P. H., and Kupperman, H. S.: The anabolic steroids, Clin. Pharmacol. & Therap. 1: 464, 1960. 104 aYielding, K. L., and Tomkins, G. M.: Steroid hormone inhibition of reduced diphosphopyridine nucleotide oxidation. Presented at the 41st Annual Session of the American College of Physicians, San Francisco, April 6, 1960. bYielding, K. L.; Tomkins, G. M.; Munday, J. S., and Cowley, I. J.: The effects of steroids on electron transport, J. Biol. Chem. 235: 3413, 1960. 105Yielding, K. L., and Tomkins, G. M.: The regulation of enzyme structure and function by steroid hormones, Am. J. Med. 33: 1, 1962. 106Gordon, G. S., and Elliott, H. W.: Action of diethylstilbestrol and some steroids on respiration of rat brain homogenates, Endocrinology 41: 517, 1947. 107Cooper, J. F., and Farid, I.: The role of citric acid in the physiology of the prostate: a chromatographic study of citric acid cycle intermediates in benign and malignant prostatic tissue, J. Surg. Res. 3: 112, 1963. 108Knox, W. E.; Auerbach, V. H., and Lin, E. C.: Enzymatic and metabolic adaptation in animals, Physiol. Rev. 36: 164, 1956. 109Villee, C. A.: Role of estrogens in regulating the metabolism of the placenta and endometrium, Fertil. & Steril. 8: 156, 1957. 110Rosenkrantz, H., and Mason, M. M.: Progress report: bioevaluation of estrogenic compounds by the canine prostatic secretion method, Cancer Chemother. Rep. 20: 33, 1962. 111Mellish, C. H.; Baer, A. J., and Macias, A. C.: Experiments on the biological properties of stilbestrol and stilbestrol dipropionate, Endocrinology 26: 273, 1940. 112 aMusa, B. U.; Seal, U. S., and Doe, R. P.: Evaluation of certain plasma proteins in man following estrogen administration: a dose-response relationship, J. Clin. Endocrinol. & Metab. 25: 1163, 1965. bZinneman, H. H.; Musa, B. U., and Doe, R. P.: Changes in plasma and urinary amino acids following estrogen administration to males, Metabolism 14: 1214, 1965. 113Iunda, I. F.: Disputes on the hormonal treatment of prostatic adenoma and cancer, in Problems of the Therapy of Malignant Tumors, ed. by I. T. Shevchenko and S. P. Sizenko. (Russian.) Kiev, Medgiz, 1961, pp. 225–229. 114Brendler, H., and Prout, G., Jr.: A cooperative group study of prostatic cancer: stilbestrol versus placebo in advanced progressive disease, Cancer Chemother. Rep. 16: 323, 1962. 115Scott, W. W., and Brandes, D.: The duality of the human prostate. Presented before Section on Urology of American Medical Association, Atlantic City, June 20, 1963. 116Tower, W. E., and Johnston, R. L.: Further studies on experimental work on probable causes of prostatic hypertrophy, J. Urol. 26: 599, 1931. 117Slaunwhite, W. R.; Sandberg, A. A.; Jackson, J. E., and Staubitz, W. J.: Effect of estrogen and HCG on androgen synthesis by human testes, J. Clin. Endocrinol. & Metab. 22: 992, 1962. 118Li, C. H.: Pituitary growth hormone as a metabolic hormone, Science 123: 617, 1956. 119Moon, H. D.; Simpson, M. E.; Li, C. H., and Evans, H. M.: Neoplasms in rats treated with pituitary growth hormone. I. Pulmonary and lymphatic tissues, Cancer Res. 10: 297, 1950. 120Moon, H. D.; Simpson, M. E.; Li, C. H., and Evans, H. M.: Neoplasms in rats treated with pituitary growth hormone. II. Adrenal glands, Ibid., p. 364. 121Moon, H. D.; Simpson, M. E.; Li, C. H., and Evans, H. M.: Neoplasms in rats treated with pituitary growth hormone. III. Reproductive organs, Ibid., p. 549. 122Moon, H. D.; Simpson, M. E.; Li, C. H., and Evans, H. M.: Neoplasms in rats treated with pituitary growth hormone IV. Absence of neoplasm in hypophysectomized rats, Cancer Res. 11: 535, 1951. 123Beck, J. C.: Personal communication. 124Ratner, A., and Meites, J.: Depletion of prolactin inhibiting activity of rat hypothalamus by estradiol or suckling stimulus, Endocrinology 75: 377, 1964. 125Pearson, O.: Personal communication. 126 aRamirez, V. D., and McCann, S. M.: Induction of prolactin secretion by implants of estrogen into the hypothalamo-hypophysial region of female rats, Endocrinology 75: 206, 1964. bSchalch, D. S.; Pincus, R. A., and Winter, M.: Regulation of growth hormone release from the pituitary gland in vitro, Clin. Res. 13: 533, 1965. 127Ramirez, V. D.; Abrams, R. M., and McCann, S. M.: Effect of estradiol implants in the hypothalamo-hypophysial region of the rat on the secretion of luteinizing hormone, Endocrinology 75: 243, 1964. 128Kanematsu, S., and Sawyer, C. H.: Effects of intrahypothalamic and intrahypophysial estrogen implants on pituitary and plasma LH in ovariectomized rabbits. Abstract 62, Program of the 45th Annual Meeting of The Endocrine Society, Atlantic City, June 13–15, 1963. 129Doc, R. P., and Mellinger, G. T.: Circadian variation of serum acid phosphatase in prostatic cancer, Metabolism 13: 445, 1964. 130Doe, R. P.: Personal communication. 131Troop, R. C., and Possanza, G. J.: Gonadal influence on the pituitary-adrenal axis, Arch. Biochem. 98: 44, 1962. 132Nakano, K.: Endocrinological study of prostatic carcinoma: effects of antiandrogenic treatments on urinary 17-ketosteroid and its fractionation (Jap.), Nippon Hinyokika Gakkai Zasshi 52: 1047, 1961. 133Sprunt, J. G., and Nelson, D. H.: The effect of estradiol on adrenal 11 β-hydroxylase activity of the male rat. Abstract 218, Program of the 47th Meeting of the Endocrine Society, New York City, June 17–19, 1965. 134Robertson, M. E.; Stiefel, M., and Laidlaw, J. C.: The influence of estrogen on the secretion, disposition and biologic activity of cortisol, J. Clin. Endocrinol. & Metab. 19: 1381, 1959. 135Kohn, G. L.; Dunn, B., and Rzasa, A.: The effect of alloxan-diabetes and estrogens upon steroid sulfokinases in the rat. Abstract 125, Program of the 47th Annual Meeting of The Endocrine Society, New York City, June 17–19, 1965. 136Moguilevsky, J. A.; Torres, H. N.; Bur, G. E.; Erenfryd, A. N., and Malinow, M. R.: Changes in the concentration of ascorbic acid induced by estradiol on endocrine glands of male rats, Acta physiol. Lat. Am. 10: 52, 1960. 137Foglia, V. G.; Borghelli, R. F.; Chieri, R. A.; Fernandez-Collazo, E. L.; Spindler, I., and Wesely, O.: Sexual disturbances in the diabetic rat, Diabetes 12: 231, 1963. 138Mestman, J. H., and Nelson, D. H.: Inhibition by estrogen administration of adrenal-pituitary response to methopyrapone, J. Clin. Invest. 42: 1529, 1963. 139Goodner, C. J.: Effects of insulin upon glucose metabolism and protein synthesis by the anterior pituitary in vitro, Diabetes 15: 115, 1966. 140Joslin, E. P.; Root, H. F.; White, P., and Marble, A.: The Treatment of Diabetes Mellitus, ed. 10. Philadelphia, Lea & Febiger, p. 61. 141 aRoth, J.; Glick, S. M.; Yalow, R. S., and Berson, S. A.: Hypoglycemia: a potent stimulus to secretion of growth hormone, Science 140: 987, 1963. bRoth, J.; Glick, S. M.; Yalow, R. S., and Berson, S. A.: Secretion of human growth hormone: physiologic and experimental modification, Metabolism 12: 577, 1963. 142Gordon, E. S.; Goetz, F. C., and Hamwi, G. J.: Is there really anything new in diabetes for the G. P.? Postgrad. Med. 33: 261, 1963. 143Pavlatos, F. C.; Karam, J. H.; Grodsky, G. M., and Forsham, P. H.: Serum insulin levels in acromegaly as a measure of clinical activity, Clin. Res. 12: 93, 1964. 144Briggs, J. H.; Butterfield, W. J. H., and Whichelow, M. J.: Studies of insulin sensitivity in normal subjects and in patients with acromegaly. Program, 23rd Annual Meeting, American Diabetes Association, Atlantic City, June 15, 1963. 145Rosenkrantz, H.; Gandbhir, S. S., and Mason, M. M.: The antiprostate activity of a variety of steroid and nonsteroid compounds, Cancer Chemother. Rep. 23: 1, 1962. 146Flocks, R. W.: Newer developments in the management of prostatic carcinoma, J. Am. Geriatrics Soc. 10: 1008, 1962. 147 aBlennerhassett, J. B.: Personal communication. bBlennerhassett, J. B., and Vickery, A. L., Jr.: Cited in Medical Tribune, March 29, 1965, p. 1. 148Oota, K.: How sex influences hepatocarcinogenesis? Acta Unio Internal. Cancr. 20: 575, 1964. 149Agnew, L. R. C., and Gardner, W. U.: The incidence of spontaneous hepatomas in C3H, C3H (low milk factor), and CBA mice and the effect of estrogen and androgen on the occurrence of these tumors in C3H mice, Cancer Res. 12: 757, 1952. 150Weichert, C. K., and Hale, H. B.: Inhibition of estrogenic effects on the reproductive system of the male rat by testosterone injection, Endocrinology 33: 16, 1943. 151Stafford, R. O.; Rubinstein, R. N., and Myer, R. K.: Effect of testosterone propionate on phosphatases in the seminal vesicle and prostate of the rat, Proc. Soc. Exper. Biol. & Med. 71: 353, 1949. 152Kees, O. S. R.: Clinical improvement following therapy in a case of primary adenocarcinoma of the seminal vesicle, J. Urol. 91: 665, 1964. 153Huggins, M. C., and Clark, P. J.: Quantitative studies of prostatic secretion. II. Effect of castration and estrogen injection on normal and hyperplastic prostate glands of dogs, J. Exper. Med. 72: 747, 1940. 154Scott, W. W.: An evaluation of endocrine therapy plus radical perineal prostatectomy in the treatment of advanced carcinoma of the prostate, J. Urol. 91: 97, 1964. 155Mellinger, G. T., et al.: Carcinoma of the prostate: a continuing cooperative study, J. Urol. 91: 590, 1964. 156Hamilton, T. H.: Sequences of RNA and protein synthesis during early estrogen action, Proc. Nat. Acad. Sc. 51: 83, 1963. 157Dukes, P. P., and Goldwasser, E.: Inhibition of erythropoiesis by estrogens, Endocrinology 69: 21, 1961. 158Wicks, W. D., and Kenney, F. T.: RNA synthesis in rat seminal vesicles: stimulation of testosterone, Science 144: 1346, 1964. 159Kassenaar, A.; Kouwenhoven, A., and Querido, A.: On the metabolic action of testosterone and related compounds. V. The effect of testosterone on the nucleic acid composition of seminal vesicles and kidneys of mice, Acta endocrinol. 39: 223, 1962. 160Egyhazi, E., and Hyden, H.: Experimentally induced changes in the base composition of the ribonucleic acids of isolated nerve cells and their oligodendroglial cells, J. Biophys. & Biochem. Cytol. 10: 403, 1961. 161Harrington, W. J.: Immunologic aspects of cancer therapy and nuclear warfare. Presented at the Third Fall Meeting of the American College of Physicians, Miami Beach, October 7, 1965. 162May, J. A., and Stimmel, B. F.: Do patients with cancer of the prostate gland show abnormal metabolism of therapeutic doses of the natural estrogens? J. Urol. 59: 396, 1948. Citing Literature Volume14, Issue7July 1966Pages 657-701 ReferencesRelatedInformation